cells

Colorectal Clinical Trials

Colorectal Cancer (ARC-3)

Overview

A Phase 1/1b open-label dose-escalation and dose-expansion trial to evaluate the safety, tolerability, PK, PD, and clinical activity of etrumadenant + mFOLFOX in participants with gastroesophageal cancer or colorectal cancer.

Key Eligibility Criteria

  • They have histologically confirmed colorectal cancer that is metastatic, advanced, or recurrent with progression
  • Participants for whom mFOLFOX is considered appropriate therapy
  • Oxaliplatin-based therapy was not the most recent regimen prior to enrolling in the trial, except if prior oxaliplatin-based therapy was received in the adjuvant setting and completed ≥ 6 months prior to trial enrollment

ARC-3 Clinical Trial Locations

clinicaltrials.gov

arrow

Colorectal Cancer (ARC-9)

Overview

A randomized Phase 1b/2, open-label, multi-center platform study to evaluate the efficacy of etrumadenant (AB928)-based combinations in patients with metastatic colorectal cancer.

Key Eligibility Criteria

  • Histologically confirmed metastatic colorectal adenocarcinoma
  • Inclusion Criteria for Cohort A:
    • Disease progression following not more than one prior line of treatment for mCRC that consisted of oxaliplatin or irinotecan containing chemotherapy in combination with a biologic agent
  • Inclusion Criteria for Cohort B:
    • Disease progression during or following not more than two separate lines of treatment for mCRC that consisted of oxaliplatin, and irinotecan containing chemotherapy in combination with a biologic agent
  • Inclusion Criteria for Cohort C:
    • Disease progression during or following more than three separate lines of treatment for mCRC

ARC-9 Clinical Trial Locations

clinicaltrials.gov

arrow

Colorectal Cancer (MORPHEUS-CRC)

Overview

A Phase 2 randomized, open-label trial to evaluate the safety, tolerability, PK, and antitumor activity of immunotherapy-based treatment combinations in participants with metastatic colorectal cancer who are refractory to first- and second-line therapies. Participants will be assigned to one of several treatment arms, including regorafenib + atezolizumab ± etrumadenant.

Key Eligibility Criteria

  • Histologically confirmed adenocarcinoma originating from the colon or rectum
  • Metastatic disease not amenable to local treatment
  • Disease progression during or following not more than 2 separate lines of treatment for metastatic colorectal cancer that consisted of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy in combination with a biologic agent
  • No prior treatment with T cell co-stimulating or immune checkpoint blockade therapies including anti-CTLA-4, anti-PD-1, and anti-PD-L1 therapeutic antibodies

Morpheus-CRC Clinical Trial Locations

clinicaltrials.gov

arrow
Next: Lung Cancer >>

Arcus Biosciences is a registered trademark of Arcus Biosciences, Inc.
© 2020 Arcus Biosciences, Inc.  All rights reserved.
3928 Point Eden Way, Hayward, CA 94545